Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 10, 2022
- Accepted in final form September 16, 2022
- First Published November 21, 2022.
Author Disclosures
- Chiara Starvaggi Cucuzza, MD,
- Elisa Longinetti, PhD,
- Nicolas Ruffin, PhD,
- Björn Evertsson, MD,
- Ingrid Kockum, PhD,
- Maja Jagodic, PhD,
- Faiez Al Nimer, MD, PhD,
- Thomas Frisell, PhD and
- Fredrik Piehl, MD, PhD
- Chiara Starvaggi Cucuzza, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Elisa Longinetti, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The Swedish Research Council for Health, Working Life, and Welfare (postdoc Grant No: 2020-0115 to E.L.)
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolas Ruffin, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
(1) Swedish StromaBio AB,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Knut and Alice Wallenberg foundation, (2) NEURO Sweden, (3) MS forskningsfonden (4) Svenska Läkaresällskapets fonder SLS-961723,
NONE
NONE
NONE
NONE
NONE
NONE
- Björn Evertsson, MD,
None
NONE
Travel grant from Roche for ECTRIMS 2018.
NONE
NONE
NONE
NONE
(1)Consultancies fees from Roche for writing a summery of ECTRIMS 2018.
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ingrid Kockum, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Stockholm county council (2018-2019) 800 000 SEK, 600 000 (2020-2021), SEK 1 750 000 (2022-2024)Karolinska Insitutet (2015-2020) PhD student funding 1 080 000 SEKEU Horizon 2020: MultipleMS consortium (2017-2021). Amount for whole consortium: 14,700 000 EURO, Share for my research group: 18 000 000 SEK EU Horizon 2020: EU STANDS-4PM consortium (2019-2021). Share for my research group: 61 875 EUROSwedish research council (2021-2024) SEK 4 800 000
NONE
100 year fonden at Karolinska Univiersity hospital during 2016 (150 000 SEK), "Hjärnfonden" during 2016, 2020-2023 as principal investigator (500 000, 600 00/year SEK respectively), Åke Löwnertz Stiftelse för Neurologisk Forskning 2018 (100 000 SEK). I have also received funding from Magareta af Ugglas Foundation (2015-2025) and PCORI (2017-2025) as co applicant.
NONE
NONE
NONE
NONE
I and my mother have held stocks in a number of mainly Swedish companies. None of them are related to this study. Only one of them is involved medical research: Novo Nordisk which my mother has shares in.
NONE
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Stockholm county council (2018-2019) 800 000 SEK, 600 000 (2020-2021), SEK 1 750 000 (2022-2024)Karolinska Insitutet (2015-2020) PhD student funding 1 080 000 SEKEU Horizon 2020: MultipleMS consortium (2017-2021). Amount for whole consortium: 14,700 000 EURO, Share for my research group: 18 000 000 SEK EU Horizon 2020: EU STANDS-4PM consortium (2019-2021). Share for my research group: 61 875 EUROSwedish research council (2021-2024) SEK 4 800 000
NONE
100 year fonden at Karolinska Univiersity hospital during 2016 (150 000 SEK), "Hjärnfonden" during 2016, 2020-2023 as principal investigator (500 000, 600 00/year SEK respectively), Åke Löwnertz Stiftelse för Neurologisk Forskning 2018 (100 000 SEK). I have also received funding from Magareta af Ugglas Foundation (2015-2025) and PCORI (2017-2025) as co applicant.
NONE
NONE
NONE
NONE
I and my mother have held stocks in a number of mainly Swedish companies. None of them are related to this study. Only one of them is involved medical research: Novo Nordisk which my mother has shares in.
NONE
- Maja Jagodic, PhD,
None
NONE
None
(1) Physiological Genomics, Editorial Board member, 2015-2021(2) Frontiers in Neurology, Associate Editor, 2017-present(3) Scientific Reports, Editorial Board member, 2018-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) European Union’s Innovative Medicines Initiative 2, EUbOPEN (875510), co-investigator, 2020-2025(2) European Research Council (ERC) Consolidator Grant, Epi4MS (818170), lead investigator, 2019-2024(3) Swedish Research Council, (2018-02638), lead investigator, 2019-2022(4) Karolinska Institutet's funds, KID, lead investigator, 2019-2023(5) European Union’s Horizon 2020 Research and Innovation Programme, MultipleMS (733161), co-lead investigator, 2017-2022(6) Stockholm County Council, ALF project (20200278), lead investigator, 2021-2022
NONE
(1) The Knut and Alice Wallenberg Foundation, (2019-0089), lead investigator, 2020-2024(2) The Brain Foundation (Hjärnfonden), (FO2021-0150), lead investigator, 2021-2024
NONE
NONE
NONE
NONE
NONE
NONE
- Faiez Al Nimer, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Swedish Brain foundation (2) Neuro Sweden
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Frisell, PhD and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The Swedish Research Council (DNR 2016-01355)
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Fredrik Piehl, MD, PhD
Data safety monitoring board member in studies with Roche and Lundbeck
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Janssen - academic research support relevant to this topic(2) Merck KGaA -academic research support relevant to this topic(1) UCB - academic research support outside of this topic
(1) Swedish Medical Research Council (grant 2020-02700) PI, 2020-ongoing.(2) Pcori, Washington DC (grant MS-1511-33196) PI, 2017-ongoing(3) European Union’s Horizon 2020 Research and Innovation Programme (MultipleMS, EU RIA 733161), co-investigator, 2017-ongoing
(1) Stockholm County (grant 20200451), PI, 2020-ongoing.
(1) the Knut and Alice Wallenberg Foundation(2) Hjärnfonden (grant FO2021-0277)
NONE
NONE
NONE
NONE
NONE
Novartis, expert witness statement, 2020-2021.
- From the Department of Clinical Neuroscience (C.S.C., E.L., N.R., B.E., I.K., M.J., F.A.N., F.P.), Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine (C.S.C., N.R., I.K., M.J., F.A.N., F.P.), Karolinska University Hospital, Stockholm, Sweden; Department of Neurology (B.E., F.P.), Karolinska University Hospital, Stockholm, Sweden; Center for Neurology (C.S.C., I.K., M.J., F.A.N., F.P.), Academic Specialist Center, Stockholm, Sweden; and Clinical Epidemiology Division (T.F.), Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Correspondence
Dr. Piehl fredrik.piehl{at}ki.se
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.